Know Cancer

or
forgot password


Phase 3
N/A
N/A
Not Enrolling
Both
Pheochromocytoma, Neuroblastoma, Paraganglioma, Medullary Thyroid Carcinoma, Carcinoid Tumors

Thank you

Trial Information


Inclusion Criteria:



- Subjects must have a clinical indication for 123I-MIBG imaging to evaluate for the
presence, extent, or status of neuroendocrine tumors;

- subjects must be able and willing to comply with study procedures.

Exclusion Criteria:

- Subjects with history of renal insufficiency (serum creatinine level > 3.0 mg/dL [265
┬Ámol/L]) and inability to be withdrawn from medications known to interfere with
123I-MIBG uptake;

- Subjects unable to tolerate lying supine;

- Subjects pregnant or breastfeeding, unless the information to be gained outweighs the
possible hazardous effects of 123I-MIBG administration. Where the assessment of the
risk/benefit ration suggests the use of 123I-MIBG in nursing mothers, the
breastfeeding should be discontinued for at least 48 hours post-injection.

Type of Study:

Interventional

Study Design:

Primary Purpose: Diagnostic

Principal Investigator

Daniel Worsley, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Vancouver Coastal Health

Authority:

Canada: Health Canada

Study ID:

H10-02695

NCT ID:

NCT01373736

Start Date:

Completion Date:

Related Keywords:

  • Pheochromocytoma
  • Neuroblastoma
  • Paraganglioma
  • Medullary Thyroid Carcinoma
  • Carcinoid Tumors
  • Carcinoid Tumor
  • Carcinoma
  • Thyroid Neoplasms
  • Neuroblastoma
  • Paraganglioma
  • Pheochromocytoma
  • Neuroendocrine Tumors

Name

Location